Do We Need Drug Therapy to Manage Mild Hypertension in the Elderly?

被引:0
|
作者
Robert H. Fagard
机构
[1] University of Leuven K.U. Leuven,Hypertension and Cardiovascular Rehabilitation Unit, Department of Molecular and Cardiovascular Research, Faculty of Medicine
[2] U.Z. Gasthuisberg - Hypertensie,undefined
来源
Drugs & Aging | 2004年 / 21卷
关键词
Left Ventricular Hypertrophy; Ambulatory Blood Pressure; Perindopril; Irbesartan; Systolic Hypertension;
D O I
暂无
中图分类号
学科分类号
摘要
Mild hypertension (grade 1 or stage 1 hypertension) is defined as a systolic blood pressure of 140–159mm Hg or a diastolic pressure of 90–99mm Hg. According to current guidelines, patients with mild hypertension can be at low, medium, high or very high risk depending on the presence of other risk factors, target organ damage and associated cardiovascular or renal conditions. Guidelines recommend prompt initiation of antihypertensive treatment in patients at very high risk because of associated clinical conditions and this recommendation is strongly supported by the literature. Also patients at high risk must be treated without much delay, but it should be mentioned that the evidence is stronger for patients who are at high risk because of diabetes mellitus, than for patients at high risk because of left ventricular hypertrophy or the accumulation of ≥3 other risk factors.
引用
收藏
页码:1 / 6
页数:5
相关论文
共 50 条
  • [41] Perioperative Antibiotics in Appendicitis-Do We Need to Adjust Therapy for the Elderly? A Matched Pair Analysis
    Strohaeker, Jens
    Brueschke, Martin
    Leser, Nora
    Koenigsrainer, Alfred
    Ladurner, Ruth
    Bachmann, Robert
    [J]. ANTIBIOTICS-BASEL, 2022, 11 (11):
  • [42] Do we need pharmacogenetics to personalize antidepressant therapy?
    Lanni, Cristina
    Racchi, Marco
    Govoni, Stefano
    [J]. CELLULAR AND MOLECULAR LIFE SCIENCES, 2013, 70 (18) : 3327 - 3340
  • [43] Do we need pharmacogenetics to personalize antidepressant therapy?
    Cristina Lanni
    Marco Racchi
    Stefano Govoni
    [J]. Cellular and Molecular Life Sciences, 2013, 70 : 3327 - 3340
  • [44] Do we need computer programme in the anomia therapy?
    Springer, Luise
    Schlenck, Klaus-Juergen
    [J]. SPRACHE-STIMME-GEHOR, 2009, 33 (04): : 212 - 212
  • [45] DO WE NEED ABDOMINAL SHELLS FOR CONFORMATION THERAPY
    DAVY, TJ
    TATE, AT
    [J]. BRITISH JOURNAL OF RADIOLOGY, 1986, 59 (704): : 810 - 810
  • [46] Hypertension in the elderly -: Can we improve results of therapy?
    Prisant, LM
    Moser, M
    [J]. ARCHIVES OF INTERNAL MEDICINE, 2000, 160 (03) : 283 - 289
  • [47] How do we explain unexplained pulmonary hypertension in the elderly?
    Rich, Stuart
    [J]. CHEST, 2007, 131 (01) : 5 - 6
  • [48] Advances in MRSA drug discovery: where are we and where do we need to be?
    Kurosu, Michio
    Siricilla, Shajila
    Mitachi, Katsuhiko
    [J]. EXPERT OPINION ON DRUG DISCOVERY, 2013, 8 (09) : 1095 - 1116
  • [49] The Benefits of Detecting and Treating Mild Hypertension: What We Know, and What We Need to Learn
    Wright, Jackson T., Jr.
    [J]. ANNALS OF INTERNAL MEDICINE, 2015, 162 (03) : 233 - 234
  • [50] Proton beam therapy - Do we need the randomised trials and can we do them?
    Glimelius, Bengt
    Montelius, Anders
    [J]. RADIOTHERAPY AND ONCOLOGY, 2007, 83 (02) : 105 - 109